Edwards Lifesciences (EW) PT Raised to $155 at Canaccord Genuity on 2Q Beat; 'Keep Buying... Upside to Raised Guidance in the Cards'

Canaccord Genuity raised its price target on Edwards Lifesciences (NYSE: EW) to $155.00 (from $150.00) while maintaining a Buy rating, following the company's second quarter earnings announcement.

Analyst Jason Mills notes the company delivered a second quarter earnings per share and revenue results above consensus projections fueled by domestic TAVR business, growing 28% year over year, reflecting the analyst's suggestion to 'keep buying.'

You May Also Be Interested In

• Take-Two Interactive (TTWO) PT Raised to $368 at BofA Securities
• Outdoor Holding (POWW) PT Raised to $2.75 at Roth/MKM, reiterates Top Pick
• Goldman Sachs Starts Lovisa Holdings Ltd (LOV:AU) at Neutral